[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP2007236395A - 二次性免疫不全症の治療用薬剤の製造方法 - Google Patents

二次性免疫不全症の治療用薬剤の製造方法 Download PDF

Info

Publication number
JP2007236395A
JP2007236395A JP2007146332A JP2007146332A JP2007236395A JP 2007236395 A JP2007236395 A JP 2007236395A JP 2007146332 A JP2007146332 A JP 2007146332A JP 2007146332 A JP2007146332 A JP 2007146332A JP 2007236395 A JP2007236395 A JP 2007236395A
Authority
JP
Japan
Prior art keywords
treatment
ncm
vivo
medium
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007146332A
Other languages
English (en)
Inventor
John W Hadden
ダブリュー ハッデン ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida filed Critical University of South Florida
Publication of JP2007236395A publication Critical patent/JP2007236395A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

【課題】天然サイトカインの特定混合物の製造方法の提供。
【解決手段】少なくとも一種のマイトジェンを組織培養容器中で固定する工程、好中球及び赤血球を含まないリンパ球の単離された集団を無血清培地中で懸濁させる工程、懸濁されたリンパ球を容器に入れる工程、リンパ球を培養する工程、培地を除去する工程及び培地をサイトカインの収率について特性決定する工程を含むとことを特徴とする天然サイトカイン混合物方法であって、１つの実施形態において、無血清培地がＸ ｖｉｖｏ−１０及びＸ ｖｉｖｏ−１５から選択される、方法。
【選択図】なし

Description

本発明はサイトカインの天然化合物の改良された製造方法に関する。
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
Figure 2007236395
本発明のその他の利点が、図面に関して考慮される時に以下の詳細な説明を参考にして良く理解されるようになるので容易に認められるであろう。
図１は、Ｘ−ｖｉｖｏ−１０（ＢＸ１０）、Ｘ−ｖｉｖｏ−１５（ＥＸ１５）、Ｘ−ｖｉｖｏ−２０（ＥＸ２０）及び最少必須培地（ＭＥＭ）中のＮＣＭのＩＬ含量（ＥＬＩＳＡにより測定されるＩＬ−１（ＩＬ２）の光学密度として表される）を示し、マイトジェンＰＨＡへの連続露出（開いたバー）をパルス化露出（クロスハッチ付き）と比較する棒グラフである。 図２は異なる培地、１×１０６／ｍｌの細胞（クロスハッチ付き）、２．５×１０６／の細胞（斜線）及び５×１０６／ｍｌの細胞（開いたバー）中１μｇ／ｍｌのＰＨＡによるＮＣＭ生成に関する細胞濃度の効果を示す棒グラフである。 図３は異なる培地、１×１０６／ｍｌの細胞（クロスハッチ付き）、２．５×１０６の細胞（斜線）及び５×１０６／ｍｌの細胞（開いたバー）中２μｇ／ｍｌのＰＨＡによるＮＣＭ生成に関する細胞濃度の効果を示す棒グラフである。 図４は、均等濃度のＩＬ−２における組換えＩＬ−２（破線）と比較したＮＣＭ（実線）によるナイーブマウスからの脾臓細胞のｉｎ ｖｉｔｒｏ処理のチミジンとり込み（ＣｏｎＡ刺激）に関する効果を示す投薬量応答グラフである。 図５は、均等濃度の１−２における組換えＩＬ−２（破線）と比較したＮＣＭ（実線）によるナイーブマウスからの胸腺細胞のｉｎ ｖｉｔｒｏ処理のチミジンとり込みに関する効果を示す投薬量応答グラフである。 図６は、ｒＩＬ−１、ｒＩＬ−２、ｒＩＬ−１＋ｒＩＬ−２またはＮＣＭによるｉｎ ｖｉｔｒｏ処理後のｒＩＬ−１（開いたバー）、ｒＩＬ−２（ソリッドバー）、ＮＣＭ（クロスハッチ付き）及びコンカナバリンＡ（斜線）に対するｉｎ ｖｉｔｒｏの脾臓細胞応答の棒グラフである。 図７は、図６のようなｉｎ ｖｉｖｏ処理後のｒＩＬ−１、ｒＩＬ−２、ＮＣＭ及びＣｏｎＡに対するｉｎ ｖｉｖｏの胸腺細胞応答の棒グラフである。 図８は、ＣＤ４＋細胞、ＣＤ８＋細胞、及びＣＤ４-／ＣＤ８-（--）細胞の脾臓細胞マーカーに関する対照（開いたバー）またはＮＣＭ（ソリッドバー）によるマウスのｉｎ ｖｉｔｒｏ処理の結果を示す棒グラフである。 図９は、ＣＤ４-／ＣＤ８-（--）、ＣＤ４＋／ＣＤ８＋（＋＋）並びにＣＤ８＋細胞とＣＤ４＋細胞（ＣＤ４＋ＣＤ８）の胸腺細胞マーカーに関する対照（開いたバー）またはＮＣＭ（ソリッドバー）によるマウスのｉｎ ｖｉｔｒｏ処理の結果を示す棒グラフである。 図１０は、対照培地（開いたバー）及びＮＣＭ（ソリッドバー）によるｉｎ ｖｉｖｏ処現後のｌＬ−１、ＩＬ−２及びＮＣＭに対するｉｎ ｖｉｔｒｏの胸腺細胞応答の棒グラフである。 図１１は、図１０と同様の脾臓細胞応答の捧グラフである。 図１２は、対照培地（開いたバー）及びＮＣＭ（閉じたバー）によるｉｎ ｖｉｔｒｏ処理後のＣｏｎＡ及びＰＨＡに対するｉｎ ｖｉｔｒｏの胸腺細胞応答の棒グラフである。 図１３は、図１２と同様の脾臓細胞応答の棒グラフである。

Claims (1)

  1. 天然サイトカイン混合物の製造法。
JP2007146332A 1994-11-17 2007-05-31 二次性免疫不全症の治療用薬剤の製造方法 Withdrawn JP2007236395A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34164594A 1994-11-17 1994-11-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005108009A Division JP2005245455A (ja) 1994-11-17 2005-04-04 二次性免疫不全症の治療用薬剤の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009150378A Division JP2009209164A (ja) 1994-11-17 2009-06-24 二次性免疫不全症の治療用薬剤の製造方法

Publications (1)

Publication Number Publication Date
JP2007236395A true JP2007236395A (ja) 2007-09-20

Family

ID=23338440

Family Applications (4)

Application Number Title Priority Date Filing Date
JP51710396A Expired - Lifetime JP4440342B2 (ja) 1994-11-17 1995-11-16 二次性免疫不全症の治療用薬剤の製造方法
JP2005108009A Withdrawn JP2005245455A (ja) 1994-11-17 2005-04-04 二次性免疫不全症の治療用薬剤の製造方法
JP2007146332A Withdrawn JP2007236395A (ja) 1994-11-17 2007-05-31 二次性免疫不全症の治療用薬剤の製造方法
JP2009150378A Withdrawn JP2009209164A (ja) 1994-11-17 2009-06-24 二次性免疫不全症の治療用薬剤の製造方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP51710396A Expired - Lifetime JP4440342B2 (ja) 1994-11-17 1995-11-16 二次性免疫不全症の治療用薬剤の製造方法
JP2005108009A Withdrawn JP2005245455A (ja) 1994-11-17 2005-04-04 二次性免疫不全症の治療用薬剤の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009150378A Withdrawn JP2009209164A (ja) 1994-11-17 2009-06-24 二次性免疫不全症の治療用薬剤の製造方法

Country Status (11)

Country Link
US (1) US5698194A (ja)
EP (1) EP0789588B1 (ja)
JP (4) JP4440342B2 (ja)
AT (1) ATE287270T1 (ja)
AU (1) AU694304B2 (ja)
CA (1) CA2205430C (ja)
DE (1) DE69533941T2 (ja)
DK (1) DK0789588T3 (ja)
ES (1) ES2236719T3 (ja)
PT (1) PT789588E (ja)
WO (1) WO1996015808A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497607B2 (ja) * 1995-05-26 2004-02-16 オリンパス株式会社 接眼光学系及びそれを用いた画像表示装置
ATE476496T1 (de) * 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
DE69810091T2 (de) * 1997-02-21 2003-10-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw., Zwijnaarde Verwendung von interleukin-15
EP1027453A4 (en) * 1997-10-17 2004-12-01 Univ South Florida METHOD FOR DIAGNOSIS AND MONITORING OF CELLULAR IMMUNE FUNCTIONS
CA2385614A1 (en) * 1999-10-13 2001-04-19 Timothy Johann Multiplex cytokine analysis
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CA2422060A1 (en) * 2000-09-12 2002-03-21 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
MXPA03003638A (es) * 2000-10-27 2004-01-26 Immuno Rx Inc Inmunoterapia con vacuna para pacientes inmunosuprimidos.
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
CA2536041A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
JP2008501697A (ja) * 2004-06-04 2008-01-24 セル‐サイ コーポレイション Ｃｄ４／ｃｄ８比及び腫瘍への単核細胞浸潤を変化させる方法
AU2005269400A1 (en) * 2004-07-30 2006-02-09 Cel-Sci Corporation A method for managing cholesterol with a serum-free and mitogen free cytokine mixture
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
MX2010005718A (es) 2007-11-28 2010-08-10 Irx Therapeutics Inc Metodo para incrementar el efecto inmunologico.
EP2276850B9 (en) * 2008-04-14 2013-10-30 IRX Therapeutics, Inc. Irx-2 modified manufacturing process
ES2679043T3 (es) 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling

Also Published As

Publication number Publication date
EP0789588A4 (en) 2001-11-28
JP2005245455A (ja) 2005-09-15
DE69533941D1 (de) 2005-02-24
ATE287270T1 (de) 2005-02-15
PT789588E (pt) 2005-05-31
WO1996015808A1 (en) 1996-05-30
US5698194A (en) 1997-12-16
CA2205430C (en) 2001-09-04
MX9703626A (es) 1998-12-31
AU4411196A (en) 1996-06-17
AU694304B2 (en) 1998-07-16
CA2205430A1 (en) 1996-05-30
JPH10510147A (ja) 1998-10-06
JP4440342B2 (ja) 2010-03-24
DE69533941T2 (de) 2005-12-29
ES2236719T3 (es) 2005-07-16
DK0789588T3 (da) 2005-05-30
EP0789588A1 (en) 1997-08-20
EP0789588B1 (en) 2005-01-19
JP2009209164A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
JP2007236395A (ja) 二次性免疫不全症の治療用薬剤の製造方法
Horibata et al. Mouse myelomas and lymphomas in culture
Adachi et al. Essential role of IL-7 receptor alpha in the formation of Peyer's patch anlage.
Foster The functions of cytokines and their uses in toxicology
Prud'homme et al. B cell dependence on and response to accessory signals in murine lupus strains.
Leffert et al. Studies on primary cultures of differentiated fetal liver cells
Yoo et al. Type II collagen autoimmunity in otosclerosis and Meniere's disease
Harris et al. Reciprocal regulation of polarized cytokine production by effector B and T cells
DeLong et al. Adaptation of the membrane lipids of a deep-sea bacterium to changes in hydrostatic pressure
Caruso et al. Cytokine production pathway in the elderly
Staudt et al. Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6
EP0791653B1 (en) Human Fc-gamma receptor III
日野明徳 et al. Ecological studies on the mechanism of bisexual reproduction in the rotifer Brachionus plicatilis. I. General aspects of bisexual reproduction inducing factors.
US5958671A (en) Methods and compositions for regulating T cell subsets by modulating transcription factor activity
JPH0411198B2 (ja)
DeLuca et al. IA-positive nonlymphoid cells and T cell development in murine fetal thymus organ cultures: interleukin 1 circumvents the block in T cell differentiation induced by monoclonal anti-IA antibodies.
Schneider et al. Sulfur dioxide-induced lymphocyte defects in human peripheral blood cultures
JPS5813396A (ja) インタ−ロイキン１存在下にインタ−ロイキン２非産生悪性化細胞株よりネズミインタ−ロイキン２を製造する方法
Ramsdell et al. CD40 ligand acts as a costimulatory signal for neonatal thymic gamma delta T cells.
KR860000895B1 (ko) 인체 성장호르몬의 제조방법
Roth et al. Regulation of gene expression in gastric epithelial cell populations of fetal, neonatal, and adult transgenic mice
Le et al. Differential regulation of mouse H-2 alloantigens
House et al. Suppression of murine cytotoxic T-lymphocyte induction following exposure to 7, 12-dimethylbenz [a] anthracene: Dysfunction of antigen recognition
Lin et al. Effects of 12-O-tetradecanoyl-phorbol-13-acetate on cell proliferation and Epstein-Barr virus DNA replication
Vickrey et al. Continuous culture of normal adult mammalian hepatocytes exhibiting parenchymal functions

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090226

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091222